The development of biotechnology and research institutes across the world has made it easier to access information about different diseases. These institutes have been supporting experts who want to find solutions to diseases that have remained a mystery for many years. In recent years, many companies in the field of biotechnology embraced research and are looking for solutions to offer easy ways of treating cancer. The success that has been witnessed so far has allowed for the development of technologies that allow patients to receive better care and specialized treatment that offers a bigger margin of success.
Seattle Genetics, one of the biotechnology companies that have invested largely in cancer research, has succeeded in the development of different drug pipelines and technologies that have been useful in treating cancer. One of their most notable drug pipelines is ADCETRIS, which has been earning the company the biggest revenue amount. ADCETRIS has proved successful and is currently adopted by over 60 countries in different parts of the world.
Another milestone that defined the dedication of Seattle Genetics to finding solutions for cancer treatment is the ADC Technology. Antibody Drug Conjugates work seamlessly in the treatment of cancer by targeting and killing harmful cells while at the same time ignoring healthy cells. This is a better technology than the radiation of waves, which kill all cells in the region targeted.
About Clay Siegall
Clay Siegall, the President, Board Chairman and CEO of Seattle Genetics, is a highly skilled clinical scientist, whose career has been confined to looking for solutions to effectively defeat cancer. He founded the company in 1998 and since then he has been supporting research and the design of products that are aimed at supporting the fight to cure cancer.
Prior to building Seattle Genetics, Clay Siegall worked at the Bristol-Meyers Squibb Research Institute (1991 to 1997). He also prior to this worked at several companies and corporations including the National Cancer Institute as well as the National Institute of Health (1988 to 1991). Clay Siegall attended the University of Maryland to study Zoology and he later joined Washington University and graduated with a PhD in Genetics.